FierceBiotech29d
Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug
Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...
pharmaphorum5d
Boehringer says R&D pipeline is the best in its long history
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of ...
With $66 million R&D center, Boehringer Ingelheim fulfills economic development pledge to state
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
Business Wire1mon
Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment
INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal ...
dvm36013d
Boehringer Ingelheim announces research and development facility expansion
The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...
‘Sick day’ on the clock: CT Biopharma firm expands patient simulations to spark creativity, empathy
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
Hosted on MSN7mon
FDA approves Boehringer’s SPEVIGO for psoriasis treatment
The US Food and Drug Administration (FDA) has granted approval for Boehringer Ingelheim's SPEVIGO injection to treat generalised pustular psoriasis (GPP). The treatment is indicated for use in adult ...
Yahoo Finance20d
Boehringer Ingelheim Expands Research and Development in Athens, Georgia
U.S. Animal Health Country Managing Director at Boehringer Ingelheim. "Each year, we invest nearly 12 percent of our sales into researching and developing products that will advance the health of ...
Business Insider1mon
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on ...
Financial Post29d
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...
The Victoria Advocate20d
Boehringer Ingelheim Expands Research and Development in Athens, Georgia
Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, producers ...